Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Bulletin Du Cancer|February 5, 1999
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]O Lavergne, D C BiggRevue Medicale De Liege|June 25, 2016
[How I TREAT... A RENAL COLIC]O Lavergne, Q Bonnet, A Thomas, et al.Revue Medicale De Liege|April 8, 2017
[Highflow priapism : diagnostic evaluation, contribution of ultrasound and recommendations]O Lavergne, A Thomas, R Andrianne, et al.Annals of the New York Academy of Sciences|February 24, 2001
Homocamptothecins: E-ring modified CPT analoguesO Lavergne, D Demarquay, P G Kasprzyk, et al.Revue Medicale De Liege|August 17, 2018
[A rare cause of cryptorchidism, the persistence of müllerian ducts syndrome]O Lavergne, E Troisfontaines, A Verstraete, et al.Journal of Chromatography. B, Biomedical Applications|March 3, 1996
Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extractionJ Pruñonosa, J Solà, C Peraire, et al.Journal of Chromatography. B, Biomedical Applications|June 23, 1995
Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extractionJ Pruñonosa, L Parera, C Peraire, et al.Anti-Cancer Agents in Medicinal Chemistry|December 17, 2008
CDC25 inhibitors as anticancer agents are moving forwardM-C Brezak, P G Kasprzyk, M-O Galcera, et al.Biochemistry|November 26, 1999
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaksC Bailly, A Lansiaux, L Dassonneville, et al.Anti-Cancer Drug Design|January 5, 2002
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38C Bailly, W Laine, B Baldeyrou, et al.Pageof 2